e-therapeutics integrates computational power and biology to accelerate the discovery of life-transforming RNAi medicines.

We have developed and validated a powerful computational approach to drug discovery, leveraging our industry-leading expertise in network biology, to fully capture and interrogate human disease complexity. Using our a proprietary GalNAc-siRNA gene silencing technology, we are harnessing internal target gene discoveries to build an in-house pipeline of next-generation RNAi based medicines.

We believe that e-therapeutics offers a differentiated strategy, with the ability to silence any gene in the liver with extremely rapid pre-clinical timelines, coupled with powerful computational capabilities, including in hepatocyte biology. We look forward to the future with great excitement.

Ali Mortazavi

Chief Executive Officer


Share price

Share price tools

Regulatory news

Regulatory news

Annual Report

Annual Report Thumbnail 1280x720.png

Latest presentation

Download a copy of our latest presentation to learn more about our Company, progress and plans. For additional presentations please visit the news and media section. 


Presentations and videos

ETX NC Overview_April22_Cover.jpg

Shareholder information

Access our shareholder centre for all essential shareholder information and to view our financial calendar.

Learn more